Abstract
Pulmonary vasoreactivity testing (PVT) with low dose adenosine predicts the clinical response to calcium channel blocker therapy in patients with pulmonary arterial hypertension (PAH). While higher dose adenosine PVT predicts the hemodynamic response to prostacyclin therapy (PGI2) after 1 year, it
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
